It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Prompt reperfusion is important to rescue ischemic tissue; however, the process itself presents a key pathomechanism that contributes to a poor outcome following cardiac arrest. Experimental data have suggested the use of levosimendan to limit ischemia–reperfusion injury by improving cerebral microcirculation. However, recent studies have questioned this effect. The present study aimed to investigate the influence on hemodynamic parameters, cerebral perfusion and oxygenation following cardiac arrest by ventricular fibrillation in juvenile male pigs. Following the return of spontaneous circulation (ROSC), animals were randomly assigned to levosimendan (12 µg/kg, followed by 0.3 µg/kg/min) or vehicle treatment for 6 h. Levosimendan-treated animals showed significantly higher brain PbtO2 levels. This effect was not accompanied by changes in cardiac output, preload and afterload, arterial blood pressure, or cerebral microcirculation indicating a local effect. Cerebral oxygenation is key to minimizing damage, and thus, current concepts are aimed at improving impaired cardiac output or cerebral perfusion. In the present study, we showed that NIRS does not reliably detect low PbtO2 levels and that levosimendan increases brain oxygen content. Thus, levosimendan may present a promising therapeutic approach to rescue brain tissue at risk following cardiac arrest or ischemic events such as stroke or traumatic brain injury.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Johannes Gutenberg-University, Department of Anesthesiology, Medical Center, Mainz, Germany (GRID:grid.5802.f) (ISNI:0000 0001 1941 7111)
2 Max Planck Institute for Polymer Research, Mainz, Germany (GRID:grid.419547.a) (ISNI:0000 0001 1010 1663)
3 Johannes Gutenberg-University, Institute for Neurosurgical Pathophysiology, Medical Center, Mainz, Germany (GRID:grid.5802.f) (ISNI:0000 0001 1941 7111)
4 Johannes Gutenberg-University, Department of Anesthesiology, Medical Center, Mainz, Germany (GRID:grid.5802.f) (ISNI:0000 0001 1941 7111); Witten/Herdecke University, Department of Anesthesiology, HELIOS University Hospital Wuppertal, Wuppertal, Germany (GRID:grid.412581.b) (ISNI:0000 0000 9024 6397)